

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**AMENDMENTS OF THE 2025 H SHARE
INCENTIVE SCHEME**

Reference is made to the circular of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) dated May 7, 2025 (the “**Circular**”) relating to, among other things, the adoption of the 2025 H Share Incentive Scheme. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Circular.

The Board is pleased to announce that it has resolved to amend the 2025 H Share Incentive Scheme (the “**2025 H Share Incentive Scheme Amendments**”) as follows:

The 2025 H Share Incentive Scheme was adopted by the Company on May 26, 2025, the key changes proposed by the 2025 H Share Incentive Scheme Amendments relates to the vesting schedule of Grants made under the 2025 H Share Incentive Scheme. Under the prior scheme rule, 3-year Award granted under the scheme will be granted before December 31, 2025, while 1-year Award are granted by the end of Q2 in each of 2025, 2026 and 2027. To provide additional flexibility to in incentivizing Eligible Participants, after the 2025 H Share Incentive Scheme Amendments, the types of Award which may be granted under the 2025 H Share Incentive Scheme are as follows:

Reward type	Award Price	Grant date
3-year Award	To be determined by the management authorized by the Board	To be granted during the duration of the 2025 H Share Incentive Scheme
1-year Award	To be determined by the management authorized by the Board	To be granted during the duration of the 2025 H Share Incentive Scheme

The Award granted will vest in accordance with the terms of the 2025 H Share Incentive Scheme. The 3-year Award and 1-year Award will vest in instalments or in full over 3 years or 1 year from the Grant Date, respectively.

Save as disclosed above, there is no other substantive change to the rules to the 2025 H Share Incentive Scheme. The Company is of the view that the 2025 H Share Incentive Scheme Amendments are procedure-related, intended to offer the Company with more flexibility and tools available for incentivizing Eligible Participants, and are not material in nature and not to the advantage of Selected Participants. The Company confirms that the amended terms of the 2025 H Share Incentive Scheme comply with all relevant requirements under Chapter 17 of the Listing Rules.

For the forgoing reasons, the Directors (including the independent non-executive Directors) are of the view that the 2025 H Share Incentive Scheme Amendments are made in line with good corporate governance standards and consider them to be in line with the interest of the Group and the Shareholders as a whole.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, June 29, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.